Skip to content

The Efficacy and Safety of Huaiqihuang Granules in the Adjuvant Treatment of Autoimmune Uveitis in Children

The Efficacy and Safety of Huaiqihuang Granules in the Adjuvant Treatment of Autoimmune Uveitis in Children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123165
Enrollment
Unknown
Registered
2026-04-22
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Uveitis in Children

Interventions

Control Group:Receive hormone therapy as part of the conventional treatment regimen
Combination Group:Huaiqihuang Granules are administered on the basis of receiving the control group treatment

Sponsors

Chengdu City Women and Children's Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 16 Years

Inclusion criteria

Inclusion criteria: 1.Pediatric patients diagnosed with autoimmune uveitis; 2. Age < 16 years old; 3.Pediatric patients who have received conventional treatment, or conventional treatment with the addition of Huaiqihuang Granules.

Exclusion criteria

Exclusion criteria: 1. Patients with diseases of other important vital organs (e.g., heart, liver, spleen, lungs, kidneys); 2. Patients allergic to Huaiqihuang Granules.

Design outcomes

Primary

MeasureTime frame
Serum Th1-type Cytokines;Serum Th2-type Cytokines;Th1/Th2 Ratio;Proportions of T Lymphocyte Subsets;NK Cell Activity;Changes in anterior chamber inflammatory cells;Visual acuity;Time to marked response;

Secondary

MeasureTime frame
Adverse Reactions;

Countries

China

Contacts

Public ContactXu Chen

Chengdu City Women and Children's Central Hospital

84646975@qq.com+86 28 6180 6000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026